Newsletter

Three Biotech Trading Ideas For A Bounce

April 12, 2005
Volume VI, Issue 34
Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com

To OTC Journal Members:
 

Comments in the BLOG

There haven't been any BLOG entries so far this week, but your comments and questions are welcome on the two most recent: DSEN and XNOM. I'll be posting a BLOG on BPTR tomorrow with some thoughts on March quarterly performance.

To use the BLOG, simply go to the home page at www.otcjournal.com - the BLOG will scroll down automatically on the right side of your screen. The most current journal entries appear in the middle of your screen. Check back frequently for updates particularly when stocks are moving to overbought or oversold levels or in volatile markets. Your questions and postings do not automatically appear, so don't bother posting the same question multiple times. I personally go through to moderate and respond to every question. If not for the filter, our BLOG would be filled with invitations to online poker sites- a total waste of the resource.

Here's three 30 day trading ideas for a long overdue bounce in the market.
 

Three Ideas For a Long Overdue Bounce

The market has been taking a fairly severe beating in '05, and is probably due for a bounce in the not too distant future. It's too early to tell if the market's recent swoon is the beginning of a bear market, or simply a correction in an ongoing bull market, but a relief rally is definitely in the cards. 

The biotech index is making a reasonably good showing, and will be one of the leaders in a long overdue bounce. Biotechs have been stealthily moving up the charts. One could argue biotechs are not effected by oil prices, consumer sensitive, or interest rate driven. Biotech breakthroughs lead to profits: plain and simple.

A chart of the Biotech index suggests it wants to stay above its .618 retracement level as measured from the August '04 low to the December '04 high. The index has twice tested that level recently and bounced convincingly both times. The current pullback poses an excellent entry point into today's ideas.  Most of the trend and directional indicators have moved into positive territory, which suggests this move may only be the beginning. Since the overall market looks far worse than the biotech group, please adhere to the suggested stop losses.

Here's three ideas with tight stops for a little relief rally:

Protein Design Labs (Nasdaq: PDLI) had a huge one day move in March and has pulled back to a more attractive entry point at the .618 retracement level. We aren't showing it on this chart, but the .618 retracement level for this stock as measured from the big jump in March is $15.31. A stop at $14.49 gives it plenty of breathing room with a profit target of at least $17.25. 

The stock has pulled back from the March high of $17.75, as is since setting up a pattern of higher lows and higher highs. As I write today's edition, the stock is trading at $15.59, down $.11 on a pretty ugly day. 

Profit target over the next thirty day: $17.25 or better. Stop Loss: $14.49.

Boston Scientific (NYSE: BSX) has been battered for months, but delivered its first meaningful bounce in over a year last week when it arrived at the $28 level. It could very well have reversed its long-term downward trend, and now have tremendous upside potential in the coming months. Since its move last week, it has also pulled back and is poised for a nice entry level at current levels. 

This stock might want to go back and fill its gap at $29.45 before heading higher. Therefore, a stop loss at 29.10 is recommended.  Profit target on BSX is no less than the $34 area, but if you're looking for a great long-term position, BSX could yield some very nice returns.  As I write today's edition, the stock is trading at $30.65, up $.10 on the day.

The infamous Imclone (NASDAQ: IMCL) of Martha Stewart and Sam Waschel fame is my third choice. This stock is the riskiest of the three, but might have the most upside potential. 

The stock is currently in the process of trying to confirm a long-term directional change, much like the one BSX made last week. We've included a 3x3 displaced moving average in a small chart for reference. The importance of this is simple. The stock broke above the 3x3 on 4/5 and closed, yesterday it broke below it and closed, we'd like to see it break above and close one more time and hold within a .618 retracement of the move for a long trade confirmation. If it can stay above $33.99, it may be in for a big move. 

The stock is currently trading at $35, up $.40 on a day when the markets are getting clobbered.

Profit Target on IMCL over the next 30 days: $39. Stop Loss: $33.99. I'm suggesting risking one point in this shaky market environment.

If these ideas work, the microcaps won't be far behind.



 
Disclaimer
The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features.  Likewise, this newsletter is owned by MarketByte, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. 

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services. 

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $140,0000 in Dutchess Private Equities II LP (“the Dutchess Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner.  No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Dutchess Limited Partnership.  The Dutchess Limited Partnership is one of two hedge funds managed by Dutchess Advisors.  Dutchess Advisors periodically refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter.  Dutchess Advisors may or may not own shares in the companies that it so refers to MarketByte.  MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Dutchess Advisors owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 3525 Del Mar Heights Rd #334, San Diego, CA 92130.


Unsubscribe Here

You can unsubscribe from this list at any time by Clicking Here and HITTING SEND. If you are having difficulty removing yourself or wish to change your address please go to http://listserv.otcjournal.com/opt.cgi?.

 
 

Disclaimer

The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies and receives compensation from them or third parties as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer’s securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.

All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.

The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the express written consent of the editors of otcjournal.com.

UNSUBSCRIBE

You can unsubscribe from this list at any time by Clicking Here. If you are having difficulty removing yourself or wish to change your address please go to http://www.otcjournal.com/opt/.